Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Esperion Therapeutics, Inc.

< Previous 1 2 3 Next >
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in Upcoming Jefferies London Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Report Third Quarter 2024 Financial Results on November 7
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Report Second Quarter 2024 Financial Results on August 12
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in Upcoming BTIG Biotech Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in Upcoming June Investor Conferences
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Reports First Quarter 2024 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in Upcoming May Investor Conferences
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Report First Quarter 2024 Financial Results on May 7
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.